Eli Lilly is set to establish a production base in South Korea for its highly successful GLP-1 obesity treatment, Mounjaro. This marks the first time a GLP-1 obesity drug will be produced in the country. The move is part of an effort to create an integrated production system in the North Chungcheong Province. Under the new arrangement, SK pharmteco, a subsidiary of SK, will manufacture the peptide, which is the active pharmaceutical ingredient (API) for Mounjaro. Another partner will then handle the manufacturing of the finished drug under a contract development and manufacturing organization (CDMO) system. Eli Lilly is expected to make an official announcement about these plans before the end of the year.